Chiara Mercinelli

Genito-Urinary Medical Oncologist at IRCCS San Raffaele Hospital - PhD Candidate in Molecular Medicine at Vita-Salute San Raffaele University

[UroToday.com @urotoday]

Outcomes of Patients with #MIBC Who Declined Radical Cystectomy in Perioperative Therapy Trials Conducted at San Raffaele Comprehensive Cancer Center. Presented by @CMercinelli @SanRaffaeleMI. #ESMO26 written coverage by @rksayyid @UAUrology > https://t.co/e0SB3MklYI #BladderCancer #GUOnc @myESMO

[Shilpa Gupta @shilpaonc]

Huge congrats @AndreaNecchi & team on this yet another novel trial.
You are always pushing the envelope in bladder cancer!
@CMercinelli @BrigidaMaiorano @giannatempopatr @UroDocAsh @montypal @PGrivasMDPhD @SpiessPhilippe @IBCG_BladderCA

[Andrea Necchi, MD, FASCO @AndreaNecchi]

This further #ESMO26 @ESMO_Open simultaneous publication is very important for me. @SanRaffaeleMI @MyUniSR
Outcomes of pts with MIBC who decline RC in perioperative setting:
Take-home message:
1. cCR (Milan criteria) is a reliable biomarker and indicator of outcomes with Systemic Rx and reTURBT
2. Pts who do not get cCR could have a very poor prognosis under bladder-saving approaches > intensification with RC/chemoRT is very much needed

Looking forward to ongoing trials (eg EV209, EV309). Congrats to the entire team, also getting Best Poster! @OncoAlert @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @urotoday Piacentini Nasso Serafin et al.

Outcomes of patients with muscle-invasive bladder cancer who declined radical cystectomy in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center - ESMO Open https://t.co/VhOHVA1GWH

[Andrea Necchi, MD, FASCO @AndreaNecchi]

With #GDFatherNeo #ESMO26 We brought visugromab+nivo combination neoadjuvantly in pts with MIBC after the initial phase 1 data in refractory setting.
33% CR rates vs 8% Nivo+placebo
All pCR pts still event-free (median FUP 15.7m)
Only 1 relapse event in major responders in N+V arm (pTa relapse)
4/5 pCR skipped RC in N+V arm.
Safety was quite good.
Pre-existing CD8+ infiltration associated with N+V Response.
It was an illuminating academic-industry collaboration for me.
Results simultaneously released today in @NatureMedicine
@myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @giannatempopatr @DrIacovelli @ciccarese_c and Many more @SanRaffaeleMI @MyUniSR

https://t.co/RUvImBFXs9

[Petros Grivas @PGrivasMDPhD]

Fantastic presentation by expert @AndreaNecchi ENERGIZE trial that did not meet its primary endpoint. Interesting ctDNA data;awaiting VOLGA trial at @myESMO #ESMOAmbassadors @OncoAlert @Uromigos @nataliagandur @DrKarineTawagi @shilpaonc @UroDocAsh @CMercinelli @BrigidaMaiorano

[UroToday.com @urotoday]

Defining clinical complete response after neoadjuvant therapy in #MIBC. @TomFlaigMD @CUAnschutz and @CMercinelli @SanRaffaeleMI join @pjhensley11 @UKYMedicine at #IBCG2026; Dr. Flaig calls #IMvigor011 a turning point for ctDNA. #WatchNow on UroToday > https://t.co/LMHl8IeTpF #IBCG26 @IBCG_BladderCA @UroDocAsh

[Urology Times @UrologyTimes]

WATCH: Chiara Mercinelli, MD, (@CMercinelli) discusses a meta-analysis comparing neoadjuvant treatment strategies for cisplatin-eligible muscle-invasive bladder cancer. https://t.co/lt4VWORlRs

[Global Society of Rare Genitourinary Tumors @GTumors]

To mark Penile Cancer Awareness Day, the GSRGT is proud to officially launch PCARE — our new patient advocacy initiative supporting people affected by #PenileCancer.

If you are a patient or caregiver looking for support or guidance, please contact us at [email protected] 📩

Special thanks to @SpiessPhilippe, @LuisMedinaMD, and @JadChahoud for bringing this initiative to life.

@drgaganprakash @npaesa @CMercinelli @CurtisPettaway1 @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @herneygarcia @PGrivasMDPhD @UroDocAsh @spsutkaMD @montypal @shilpaonc @orchidcancer @karima_oualla @VedangMurthy @UrogerliMD

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

🧬 Could PSMA PET/CT become more than a staging tool—and actually help us measure treatment response?

Article 📰
https://t.co/hJ4pKqwRXL

PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review

A systematic review of 11 studies evaluated PSMA PET/CT for treatment response assessment in hormone-sensitive #ProstateCancer .
➡️ ADT generally reduced PSMA expression, although an early flare was observed in a subset of lesions, particularly bone metastases.
➡️ Following radiotherapy ☢️ , PSMA reductions appeared greater when ADT was added.
✅ These findings suggest PSMA PET parameters could potentially help personalize treatment monitoring, but their association with long-term oncological outcomes remains to be established.

@JennKa12, @MBauckneht, @ClaudiaKesch, @GGandaglia, @dr_rajwa, @Fabio_Zattoni, @AlbertoMartini_, @veerukasi, @Lara__Rodriguez, @fazekasMD, @TheGiesen, @m_martinamaggi, @CMercinelli, @miszczyk_marcin, @JGomezRivas, @ruimmbernardino, @alibourgi1_ali, @Tilki_De, @GMarra_MD, @EAU_YAUProstate

@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists

[Antonio Cigliola @Anto_cigliola]

What do we gain by adding belzutifan to pembro in high-risk ccRCC post-nephrectomy?

Our reconstructed IPD analysis of LITESPARK-022 pembro+belzu arm vs KN-564 placebo arm, now in @ESMOOpen, reveals a compelling survival signal:

🔹 DFS: HR 0.55
🔹 OS: HR 0.56

#RCC #GUOnc

[Karima Oualla, MD,MSc @karima_oualla]

Best part of the meeting is reaching out with friends and colleagues @IBCG_BladderCA @UroDocAsh @shilpaonc @giannatempopatr @PGrivasMDPhD @AndreaNecchi @apolo_andrea @CMercinelli @BrigidaMaiorano @AparnaKamatMD @NehaVapiwala

[Karima Oualla, MD,MSc @karima_oualla]

Wonderful dinner with amazing people at the 20th anniversary of
@IBCG_BladderCA @UroDocAsh @PGrivasMDPhD @giannatempopatr @CMercinelli @spsutkaMD @carme_mir1 @BrigidaMaiorano

[Sumanta K. Pal, MD, FASCO @montypal]

Already impressed with the truly global nature of #IBCG26 - and the meeting has not even officially started yet! Hats off to @UroDocAsh for bringing #bladdercancer experts around the 🌍 to discuss key topics from #NMIBC to #mUC. Was pleased to see @karima_oualla 🇲🇦, @giannatempopatr @CMercinelli @BrigidaMaiorano 🇮🇹, @drgaganprakash 🇮🇳 & so many others - anticipating great discussions today!

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Let’s kick off #IBCG26 celebrating 20 years @IBCG_BladderCA @urotoday

[Sumanta K. Pal, MD, FASCO @montypal]

Incredible to see the growth of @IBCG_BladderCA over 20y. At #IBCG26, @UroDocAsh highlights new members (incl @WesleyYipMD @AbhiTrip87 from @cityofhope), 🌎 site (28 countries!), publications (incl @EUplatinum highest rated article from @shilpaonc @UrogerliMD et al) & society collabs (@GTumorBoard @JSUO_official @TataMemorial @SIU_urology & more). Just brilliant!

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Defining the Optimal Therapeutic Approach in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Novel Strategies Versus Gemcitabine-Cisplatin | @JCOOA_ASCO @ASCO @CMercinelli @Anto_cigliola @BrigidaMaiorano @vale_tateo @SanRaffaeleMI @MyUniSR @OncoAlert @urotoday https://t.co/1nHPOU1q5N

[Mirrors of Medicine @mirrorsmed]

🚨 Is gemcitabine-cisplatin still the benchmark in MIBC?

Article 📰 https://t.co/efv8QjoQdU

Defining the Optimal Therapeutic Approach in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Novel Strategies Versus Gemcitabine-Cisplatin

A meta-analysis of three phase III trials in cisplatin 🧪eligible muscle-invasive #BladderCancer shows that intensified or immune-based neoadjuvant regimens outperform gemcitabine-cisplatin. ✅EVP produced the strongest improvements in event-free survival, overall survival, and pathologic complete response, while GC plus durvalumab and ddMVAC also improved outcomes. ➡️However, cross-trial differences and limited follow-up warrant caution. The findings underscore a rapidly evolving perioperative landscape and raise important questions about biomarkers 🎯 , overtreatment, toxicity, and bladder preservation.

@CMercinelli
@Anto_cigliola
@BrigidaMaiorano
@UroMoschini
@F_Montorsi
@Albert0Briganti
@AndreaNecchi

[Global Society of Rare Genitourinary Tumors @GTumors]

Thank you to our growing global community for supporting the GSRGT and our mission!

Interested in rare GU tumors? Follow @gtumors and join our growing global community! 🌎

@SpiessPhilippe @drgaganprakash @npaesa @CMercinelli @AmerUrological @UroOnc @SUO_YUO @CAU_URO @JadChahoud @benristau @PGrivasMDPhD @spsutkaMD @CMercinelli @LuisMedinaMD @herneygarcia @AndreaNecchi @apolo_andrea @VedangMurthy @ARRODRIGUEZMD @montypal @UrogerliMD @dramandeeparora @CurtisPettaway1 @karima_oualla

[OncoDaily GU @OncoDailyGU]

10 Must-Read Posts in GU Oncology This Week | First Week of August

This week’s selection covers:

• PSMAddition and ¹⁷⁷Lu-PSMA-617 in PSMA+ mHSPC
�� MR-guided adaptive SBRT to the prostate bed
• Early enfortumab vedotin rash as a potential response marker
• PSA nadir as a prognostic marker in mHSPC
• Conditional survival in metastatic RCC after first-line nivo/ipi
• Unmet needs in penile cancer
• Neoadjuvant immunotherapy in MIBC: PURE-01, NureCombo, SURE2
• Nicheverse and spatial transcriptomics in ccRCC
• Enzalutamide vs darolutamide doublet therapy in mHSPC
• EORTC 2238 DE-ESCALATE in mHSPC

@katy_beckermann @shilpaonc @fcounago @g_procopio_ @LuisMedinaMD @CMercinelli @nealshore @BertrandTOMBAL @ChrisWeeMD
@AmandaNizamMD @jamecancerdoc @MosheOrnsteinMD

👉 https://t.co/BnCK4PaaT0

#GUOncology #OncoDaily

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Tumor mutational burden predicts the outcome of patients with muscle-invasive bladder cancer undergoing immune-checkpoint inhibitor-based neoadjuvant therapy - a combined analysis of #PURE01 #SURE02 #NureCombo @CMercinelli @Anto_cigliola @BrigidaMaiorano et al. @SanRaffaeleMI @MyUniSR #TMB @FoundationATCG https://t.co/xTtHLnDsJT